Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer

ClinicalTrials.gov ID: NCT00294190

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00294190. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 5:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study Of Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This proposed phase II trial will investigate weekly topotecan at a higher dose than was used in the previous trials in an attempt to achieve improved response rates and disease control without added toxicity. To help ameliorate the fatigue, planned rest weeks will be incorporated into the schedule. This trial will be the first clinical trial to evaluate a higher dose of weekly topotecan in the treatment of extensive-stage SCLC.

Study identification

NCT ID: NCT00294190
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: SCRI Development Innovations, LLC; Other
Enrollment: 38 participants

Conditions and interventions

Conditions

Interventions

Topotecan Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 2006 (Type not available)
Primary completion: Sep 2007 (Actual)
Completion: Jul 2009 (Actual)
Last update posted: Dec 10, 2012

2006 – 2009

United States locations

U.S. sites: 13
U.S. states: 10
U.S. cities: 13

Facility	City	State	ZIP	Site status
Northeast Arkansas Clinic	Jonesboro	Arkansas	72401	—
Florida Cancer Specialists	Fort Myers	Florida	33901	—
Watson Clinic Center for Cancer Care and Research	Lakeland	Florida	33805	—
Florida Hospital Cancer Institute	Orlando	Florida	32804	—
Northeast Georgia Medical Center	Gainesville	Georgia	30501	—
Consultants in Blood Disorders and Cancer	Louisville	Kentucky	40207	—
Hematology Oncology Life Center	Alexandria	Louisiana	71301	—
Grand Rapids Clinical Oncology Program	Grand Rapids	Michigan	49503	—
Methodist Cancer Center	Omaha	Nebraska	68114	—
Oncology Hematology Care	Cincinnati	Ohio	45242	—
Spartanburg Regional Medical Center	Spartanburg	South Carolina	29303	—
Chattanooga Oncology Hematology Associates	Chattanooga	Tennessee	37404	—
Tennessee Oncology, PLLC	Nashville	Tennessee	37023	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00294190, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 10, 2012 · Synced Nov 13, 2026